Literature DB >> 7081149

Carcinoma of the endometrium. II. Papillary adenocarcinoma: a clinical pathological study, 46 cases.

W M Christopherson, R C Alberhasky, P J Connelly.   

Abstract

Forty-six patients with papillary carcinoma of the endometrium were studied. Forty-five were followed for at least five years or until death, and 41 were followed for 10 years. The remaining patient was alive at four years. The survival rate was 51.1% at five years and 46.3% at 10 years. At five years one-third had died of their disease. The median age at time of diagnosis was 63 years, and the age at diagnosis was an important determinant of survival. None of the seven black women survived for five years. Tumor grade was an important predictor of the course of disease and nuclear grading was a significantly more accurate indicator than was the histologic grading of the World Health Organization. Papillary carcinoma should be distinguished from the papillary type of clear cell carcinoma of the endometrium. While it has a somewhat better prognosis than mixed adenosquamous carcinoma or clear cell carcinoma, it appears to be more aggressive with a lower survival rate and higher rate of death from disease than the usual type of endometrial adenocarcinoma or adenoacanthoma.

Entities:  

Mesh:

Year:  1982        PMID: 7081149     DOI: 10.1093/ajcp/77.5.534

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  12 in total

1.  Cytologic findings of cervicovaginal smears in women with uterine papillary serous carcinoma.

Authors:  Ji-Young Park; Hye Sun Kim; Sung Ran Hong; Yi Kyeong Chun
Journal:  J Korean Med Sci       Date:  2005-02       Impact factor: 2.153

Review 2.  Laboratory Assays in Evaluation of Lynch Syndrome in Patients with Endometrial Carcinoma.

Authors:  Bojana Djordjevic; Russell R Broaddus
Journal:  Surg Pathol Clin       Date:  2016-04-11

Review 3.  Role of the clinical pathology laboratory in the evaluation of endometrial carcinomas for Lynch syndrome.

Authors:  Bojana Djordjevic; Russell R Broaddus
Journal:  Semin Diagn Pathol       Date:  2014-04-02       Impact factor: 3.464

4.  MicroRNA signatures differentiate uterine cancer tumor subtypes.

Authors:  Elena S Ratner; David Tuck; Christine Richter; Sunitha Nallur; Rajeshvari M Patel; Vince Schultz; Pei Hui; Peter E Schwartz; Thomas J Rutherford; Joanne B Weidhaas
Journal:  Gynecol Oncol       Date:  2010-06-09       Impact factor: 5.482

Review 5.  Pathophysiology and management of endometrial hyperplasia and carcinoma.

Authors:  Y S Fu; J C Gambone; J S Berek
Journal:  West J Med       Date:  1990-07

6.  Insights into endometrial serous carcinogenesis and progression.

Authors:  Oluwole Fadare; Wenxin Zheng
Journal:  Int J Clin Exp Pathol       Date:  2009-01-10

7.  Application of Immunohistochemistry and Molecular Diagnostics to Clinically Relevant Problems in Endometrial Cancer Bojana Djordjevic, Shannon Westin, Russell R. Broaddus.

Authors:  Bojana Djordjevic; Shannon Westin; Russell R Broaddus
Journal:  Surg Pathol Clin       Date:  2012-12-01

8.  The effect of cell type on surgico-pathologic risk factors in endometrial cancer.

Authors:  Ahmet Taner Turan; Betül Dündar; Burcu Gündoğdu; Abdullah Boztosun; Nejat Ozgül; Nurettin Boran; Gökhan Tulunay; Ahmet Ozfuttu; Mehmet Faruk Köse
Journal:  J Turk Ger Gynecol Assoc       Date:  2011-03-01

9.  Management of women with surgically staged 1 uterine papillary serous cancer.

Authors:  Laurie Elit; Andre Laroche; Lauren Smith; John Mazurka; Francois Moens; Jan Hauspy; Waldo Jimenez
Journal:  ISRN Obstet Gynecol       Date:  2011-09-11

10.  Lynch syndrome related endometrial cancer: clinical significance beyond the endometrium.

Authors:  Yiying Wang; Yue Wang; Jie Li; Janiel Cragun; Kenneth Hatch; Setsuko K Chambers; Wenxin Zheng
Journal:  J Hematol Oncol       Date:  2013-03-25       Impact factor: 17.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.